Metagenomi Therapeutics (MGX) Net Income towards Common Stockholders (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Net Income towards Common Stockholders of -$23.1 million for Q1 2026, up 7.91% year-over-year from -$21.4 million in Q1 2025, and down 2.36% quarter-over-quarter from -$22.5 million in Q4 2025.
Metagenomi Therapeutics (MGX) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$23.1 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$23.1 million, up 7.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$85.9 million (down 10.18% YoY), and the FY2025 annual result was -$87.9 million, down 12.57% from the prior year.
- Net Income towards Common Stockholders slipped to -$23.1 million in Q1 2026 per MGX's latest filing, from -$22.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$10.7 million in Q2 2024 and troughed at -$25.1 million in Q1 2024.
- A 4-year average of -$19.8 million and a median of -$19.9 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders rose 17.44% in 2024, then tumbled 85.38% in 2025.
- A 4-year view of Net Income towards Common Stockholders shows it stood at -$19.3 million in 2023, then declined by 21.27% to -$23.4 million in 2024, then grew by 3.72% to -$22.5 million in 2025, then retreated by 2.36% to -$23.1 million in 2026.
- Business Quant data shows MGX's Net Income towards Common Stockholders at -$23.1 million in Q1 2026, -$22.5 million in Q4 2025, and -$20.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Metagenomi Therapeutics | 46.60 Mn | 46.60 Mn | - | -23.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.06 Mn |
| Dec 31, 2025 | -22.53 Mn |
| Sep 30, 2025 | -20.39 Mn |
| Jun 30, 2025 | -19.91 Mn |
| Mar 31, 2025 | -25.04 Mn |
| Dec 31, 2024 | -23.40 Mn |
| Sep 30, 2024 | -18.77 Mn |
| Jun 30, 2024 | -10.74 Mn |
| Mar 31, 2024 | -25.15 Mn |
| Dec 31, 2023 | -19.29 Mn |
| Sep 30, 2023 | -19.82 Mn |
| Jun 30, 2023 | -13.01 Mn |
| Mar 31, 2023 | -16.13 Mn |